Get the Stockscreener App
73.77
0.07%
0.05
After Hours:
71.35
-2.42
-3.28%
Incyte Corp Stock (INCY) Latest News
Incyte's SWOT analysis: stock faces patent cliff challenge amid pipeline promise - Investing.com
Union Bancaire Privee UBP SA Buys Shares of 4,500 Incyte Co. (NASDAQ:INCY) - MarketBeat
Nisa Investment Advisors LLC Has $1.56 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
KBC Group NV Sells 104,419 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Patton Albertson Miller Group LLC Increases Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
SG Americas Securities LLC Grows Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Royal Bank of Canada Reiterates Sector Perform Rating for Incyte (NASDAQ:INCY) - MarketBeat
Royal Bank of Canada Reaffirms "Sector Perform" Rating for Incyte (NASDAQ:INCY) - MarketBeat
Incyte's SWOT analysis: strong pipeline faces patent cliff challenges - Investing.com
Steven H. Stein Sells 12,352 Shares of Incyte Co. (NASDAQ:INCY) Stock - MarketBeat
INCY (Incyte) Growth Rank : 8 (As of Jan. 23, 2025) - GuruFocus.com
Insider Decision Unfolding At Incyte: Matteo Trotta Exercises Options, Resulting In $0 - Benzinga
In A Strategic Move, Christiana Stamoulis Acquires Incyte Stock Options Worth $8K: Enhancing Value - Benzinga
Vijay Iyengar Backs Up Beliefs With A Notable Acquisition Of Incyte Stock Options Worth $5K - Benzinga
PAULA SWAIN Decides To Exercise Options At Incyte Worth $0 - Benzinga
Whalen Wealth Management Inc. Invests $245,000 in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Bought by Crossmark Global Holdings Inc. - MarketBeat
Merit Financial Group LLC Invests $624,000 in Incyte Co. (NASDAQ:INCY) - MarketBeat
Drug Co. Wants To Keep Judge On Alopecia IP Case - Law360
Incyte corp EVP Steven Stein sells shares worth $897,866 By Investing.com - Investing.com Canada
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
William Blair Issues Pessimistic Outlook for Incyte Earnings - MarketBeat
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results - Yahoo Finance
Incyte Gains 15.3% In A Year: Is There Room For Further Growth? - Barchart
Incyte Gains 15.3% in a Year: Is There Room for Further Growth? - Yahoo Finance
Short Interest in Incyte Co. (NASDAQ:INCY) Decreases By 13.1% - MarketBeat
INCY (Incyte) GF Value Rank : 8 (As of Jan. 20, 2025) - GuruFocus.com
Hennion & Walsh Asset Management Inc. Purchases 11,120 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
What You Need To Know Ahead Of Incyte's Earnings Release - Barchart
Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials - MSN
Fed. Circ. Urged To Keep Block Of Sun Pharma Alopecia Drug - Law360
Contravisory Investment Management Inc. Has $750,000 Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CHURCHILL MANAGEMENT Corp Has $12.36 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Claro Advisors LLC Takes Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
JP Morgan 2025: Incyte expects period of ‘defining catalysts’ - Yahoo Finance
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Rigel Pharma, Incyte Crp., Sanofi, Johnson & Johnson, Janssen R&D - Barchart
Incyte's SWOT analysis: navigating patent cliff with promising pipeline - Investing.com
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
DPP-led Effort For Incyte Leads To Deal Of The Year Honors - Town Square Delaware LIVE
Incyte's (INCY) "Market Perform" Rating Reiterated at JMP Securities - MarketBeat
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline - Benzinga
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised - openPR
Pallas Capital Advisors LLC Makes New $1.01 Million Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Has Incyte (INCY) Outpaced Other Medical Stocks This Year? - MSN
Anal Cancer Market on Track for Major Expansion by 2034, - openPR
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.29 - MarketBeat
Incyte: Multiple Drug Launches Bode Well For Future Growth - Seeking Alpha
Incyte (NASDAQ:INCY) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Incyte Corporation (INCY) Announces Executive Leadership Change - GuruFocus.com
Incyte Announces Retirement of Executive VP Barry Flannelly - TipRanks
JPMorgan Chase & Co. Reduces Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 - BioSpace
Incyte (MEX:INCY) Earnings Yield % : 0.09% (As of Jan. 08, 2025) - GuruFocus.com
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
CWA Asset Management Group LLC Acquires Shares of 27,984 Incyte Co. (NASDAQ:INCY) - MarketBeat
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):